Sells a point-of-care EEG system that combines portable hardware and AI algorithms to help hospitals detect and monitor seizures and other neurological conditions in critically ill patients.
10-K for FY2025, filed Feb 24, 2026We are a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions.…View ↗
We specifically designed the Ceribell System to address the limitations of conventional EEG in the acute care setting and dramatically…View ↗
In December 2025, the FDA granted 510(k) clearance for our proprietary delirium monitoring solution, the first and only FDA cleared…View ↗
Hospitals pay for disposable Wearables and a subscription to use Clarity, recorders and the portal. Wearables are paid for when delivered; subscription fees are paid monthly or annually and cover access over the subscription period.
10-K for FY2025, filed Feb 24, 2026We generate revenue primarily from two recurring sources – the sale of our single use, disposable Wearables and a monthly subscription fee…View ↗
We generate revenue primarily from two recurring sources – sales of our disposable Wearables which are intended for single patient use, and…View ↗
The majority of customers are invoiced for subscription fees monthly in advance, with all amounts due generally within 30 days of the date…View ↗
The Company’s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force throughout…View ↗
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗$89.1M
10-K for FY2025, filed Feb 24, 2026
$89.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
76% |
Product revenue, FY2025
$67.3M Sources
|
Sold outright |
|
Subscription revenue
Recurring
10-K for FY2025, filed Feb 24, 2026 |
24% |
Subscription revenue, FY2025
$21.7M Sources
|
Recurring |
Hospitals and medical groups buy the system through Ceribell’s U.S. direct sales organization. Hospital clinicians and executives take part in evaluating and adopting it, with account teams supporting onboarding and ongoing use.
10-K for FY2025, filed Feb 24, 2026The Company’s revenue is derived from the sale of its products to medical groups and hospitals through its direct sales force throughout…View ↗
We generate revenue primarily from two recurring sources – the sale of our single use, disposable Wearables and a monthly subscription fee…View ↗
Our TMs drive adoption of the Ceribell System in new accounts by engaging with key decision makers to introduce the compelling value…View ↗
Our CAMs are focused on driving increased utilization and penetration within existing accounts, ongoing account coverage, and further…View ↗
No. It lost $53.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 3, 2026
−$21.4MView ↗
10-Q for Q3 FY2026, filed Nov 3, 2026
Open tableView ↗
8-K, filed Aug 10, 2026
Ceribell is raising its revenue guidance for the full year 2026 to a range of $114 million to $117 million, representing growth of…View ↗
Competes with Natus Medical, Nihon Kohden, Zeto, and Natus
10-K for FY2025, filed Feb 24, 2026The primary competition that we face is from conventional EEG systems, which are used in the majority of hospitals in the United States.…View ↗
Loading...